Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Categorized Hematologic Response to Pegcetacoplan Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis of Data from a Phase 3 Randomized Trial (PEGASUS)

Antonio Risitano, Ilene C. Weitz, Carlos M. de Castro, MD, Jean-Jacques Kiladjian, Morag Griffin, MBChB, FRCPath, Hisakazu Nishimori, MD PhD, Mohamed Hamdani, Temitayo Ajayi, Scott B. Baver, PhD, Regis Peffault De Latour, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-142166

Published: 2020

Journal Articles

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen, MBChB, PhD, Jeffrey Szer, MBBS, Ilene C. Weitz, Alexander Röth, MD, Britta Hoechsmann, Jens Panse, MD, Kensuke Usuki, MD PhD, Morag Griffin, MBChB, FRCPath, Jean-Jacques Kiladjian, MD PhD, Carlos M. de Castro, MD, Hisakazu Nishimori, MD PhD, Lisa Tan, Mohamed Hamdani, Pascal Deschatelets, PhD, Cedric Francois, MD PhD, Federico Grossi, MD, Antonio Risitano, Regis Peffault De Latour, MD PhD

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-142174

Published: 2020

Journal Articles

Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement

Regis Peffault De Latour, MD PhD, Carlos M. de Castro, MD, Jeffrey Szer, MBBS, Kensuke Usuki, MD PhD, Peter Hillmen, MBChB, PhD, Morag Griffin, MBChB, FRCPath, Mohamed Hamdani, MS, Temitayo Ajayi, Hisakazu Nishimori, MD PhD, Ilene C. Weitz

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-141061

Published: 2020

Journal Articles

Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab

Alexander Röth, MD, Britta Hoechsmann, Morag Griffin, MBChB, FRCPath, Carlos M. de Castro, MD, Jeffrey Szer, MBBS, Kensuke Usuki, MD PhD, Juliette Soret, MD, Mohamed Hamdani, MS, Temitayo Ajayi, Sujata P. Sarda, PhD, Jens Panse, MD

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-134581

Published: 2020

Journal Articles

Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia

Anthony D. Sung, MD, Carlos M. de Castro, MD, Thomas W. LeBlanc, MD MA, Gwynn D. Long, MD, Donna B. Adams, NP, Danielle M. Brander, MD, Sandeep Dave, MD, Louis F. Diehl, MD, Phuong Linh Doan, MD, Therese Hennig, PA, Yubin Kang, MD, Matthew S. McKinney, MD, Lindsay A.M Rein, MD, Dorothy A. Sipkins, MD, Yiping Yang, MD PhD, Nelson J. Chao, MDM.B.A, David A. Rizzieri, MD

Blood (2017) 130 (Supplement 1): 3853.

https://doi.org/10.1182/blood.V130.Suppl_1.3853.3853

Published: 2017

Journal Articles

Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia,

Tod A. Morris, MD, David A. Rizzieri, MD, Carlos M de Castro, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Anand S. Lagoo, MD, PhD, Joseph O. Moore, MD, Arati V Rao, MD

Blood (2011) 118 (21): 3590.

https://doi.org/10.1182/blood.V118.21.3590.3590

Published: 2011

Journal Articles

Maintenance Therapy with Low-Dose Subcutaneous 5-Azacitidine in Older Patients with AML in 1st Remission.

Jeffrey E Lancet, MD, Rami S. Komrokji, MD, HuiYi Lin, Carlos M. de Castro, MD, David A. Rizzieri, Magda Melchert, Alan F List, MD

Blood (2009) 114 (22): 1029.

https://doi.org/10.1182/blood.V114.22.1029.1029

Published: 2009

Journal Articles

The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.

Dale J. Christensen, PhD, Karen M. Bond, BS, Alicia D. Volkheimer, MS, Jessica Oddo, BS, Youwei Chen, MD, Jon P. Gockerman, MD, Joseph O. Moore, MD, Louis F. Diehl, MD, Carlos M. de Castro, MD, Michael P. Vitek, PhD, J. Brice Weinberg, MD

Blood (2009) 114 (22): 802.

https://doi.org/10.1182/blood.V114.22.802.802

Published: 2009

Journal Articles

Apolipoprotein E-Mimetic Therapeutic Peptides Mediate CLL Cell Cytotoxicity

Blood (2008) 112 (11): 359.

https://doi.org/10.1182/blood.V112.11.359.359

Published: 2008

Journal Articles

Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro.

J. Brice Weinberg, MD, Ning Jiang, MD, Alicia D. Volkheimer, MS, Youwei Chen, MD, Karen M. Bond, BS, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Carlos M. de Castro, MD, David A. Rizzieri, MD, PhD, Marc C. Levesque, MD, PhD, Kenneth Mugridge, PhD, Joe DeAngelo

Blood (2007) 110 (11): 3129.

https://doi.org/10.1182/blood.V110.11.3129.3129

Published: 2007

Journal Articles

Apolipoprotein E (APOE) Genotype as a Determinant of Survival in Women with Chronic Lymphocytic Leukemia.

J. Brice Weinberg, MD, Alicia D. Volkheimer, MS, Mirta Mihovilovic, PhD, Ning Jiang, MD, Youwei Chen, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Carlos M. de Castro, MD, David A. Rizzieri, MD, Marc C. Levesque, MD, PhD, Robert DeKroon, PhD, Warren J. Strittmatter, MD

Blood (2007) 110 (11): 3081.

https://doi.org/10.1182/blood.V110.11.3081.3081

Published: 2007

Journal Articles

Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Carlos M. De Castro, MD, John Ellerton, MD, Kathryn N. Knapp, MS, C.L. Beach, PharmD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2526.

https://doi.org/10.1182/blood.V106.11.2526.2526

Published: 2005

Journal Articles

Campath-1H May Have Activity in the Treatment of Multiple Myeloma.

Cristina Gasparetto, MD, Mitchell E. Horwitz, MD, Jon P. Gockerman, MD, Carlos M. de Castro, MD, Joseph O. Moore, MD, Clay A. Smith, MD, Patty Davis, Martha Lassiter, Lesa Houser, Nelson J. Chao, MD, David Rizzieri, MD

Blood (2004) 104 (11): 4931.

https://doi.org/10.1182/blood.V104.11.4931.4931

Published: 2004

NARROW

Categorized Hematologic Response to Pegcetacoplan Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis of Data from a Phase 3 Randomized Trial (PEGASUS)

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement

Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab

Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia

Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia,

Maintenance Therapy with Low-Dose Subcutaneous 5-Azacitidine in Older Patients with AML in 1st Remission.

The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.

Apolipoprotein E-Mimetic Therapeutic Peptides Mediate CLL Cell Cytotoxicity

Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro.

Apolipoprotein E (APOE) Genotype as a Determinant of Survival in Women with Chronic Lymphocytic Leukemia.

Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.

Campath-1H May Have Activity in the Treatment of Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only